Adalta Ltd has released a press release.
Appendix 4C - quarterly
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from AdAlta
- AdAlta Granted US Patent for AD-214
- AD-214 Phase I strategy and timing update
- AdAlta awarded Biomedical Translation Bridge Funding
- GLP Toxicology study results
- Tim Oldham Appointed as Chief Executive Officer
Later from AdAlta
- AD-214 effective in gold standard pre-clinical animal model
- Investor Briefing - Strategic Plan
- Board changes and R&D Tax Incentive advance received
- Business update and COVID-19 response
- AdAlta receives approval to commence AD-214 Phase I trial
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta